Abstract: (1) A composition which comprises erythropoietin and hyaluronic acid shows a sustained-release of the medicine in a living body, and(2) A water-soluble composition which comprises (a) a pharmacologically active polypeptide secreted by an animal body or its derivative or a chemically synthesized pharmacologically active substance, (b) a water-soluble species' of hyaluronic acid or its nontoxic salt and (c) a water-soluble protein injectable into body fluids without showing any substantial pharmacological activity brings about a prolonged action in vivo of a pharmacologically active substance. In addition, the composition can be administered using a small-gauge needle and thereby contributes to relieving pain in patients.
Abstract: Deteriorating developer including toner and carrier in a developer container is replaced by supplying carrier developer including carrier from a developer supply unit and discharging an amount of the deteriorated developer corresponding to the amount of the supplied carrier developer through a discharge opening formed in the developer container by opening a cover. The cover is driven by a solenoid for discharging. With this structure, even when the amount of developer in the developer container is changed and the surface level of the developer is changed, a predetermined amount of deteriorated developer is accurately discharged according to the driving of the cover. It is thus possible to control in a desired manner the replacement ratio of deteriorated developer in the developer container to new developer to be supplied. With this configuration, it is possible to maintain the charge of developer substantially uniform and good image quality of copies.
Abstract: A container and closure are described. The container has a circular sidewall with a bottom and an open end defining a volume for containing a liquid, the sidewall having (i) a reinforced rim at the open end, (ii) a lid seat integrally formed in the sidewall and offset from the open end, (iii) a comfort zone extending along the sidewall from the bottom to the open end and (iv) a rim tab located on the inside of the container sidewall at the comfort zone adjacent the open end. The rim tab extends beyond the open end of the container. The closure is a circular substrate having (a) a diameter to seat in the lid seat of the container, (b) a plurality of peripheral tabs extending beyond the diameter of the substrate and (c) a pull tab located near an outer edge of the substrate which when pulled provides an opening through which liquid can pass when the closure is seated in the lid seat of the container.
Abstract: The present invention discloses a method for inhibiting tissue damage in mammals caused by pathological NO production, which comprises administering an effective tissue damage inhibition amount of a NO synthase inhibitor to said mammal. Preferably the NO synthase inhibitor is L-NMMA.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
December 17, 1996
Assignee:
Glaxo Wellcome Inc.
Inventors:
Salvador E. Moncada, Richard M. J. Palmer
Abstract: An apparatus for producing an object using stereography is disclosed. The apparatus has a bath of liquid material in a container, the bath having a free surface. A support in the container supports and positions the object relative to the surface. A means for applying electromagnetic radiation solidifies a layer having solidified sections of the material. A wiper extends across the surface in a first direction. The wiper is at least partly formed of a flexible material and has a substantially horizontal lower edge, and it is positioned below the free surface of the bath in a working position. Displacement means displaces the wiper in the working position in a second direction substantially transversely to the first direction to move a portion of the liquid material in the bath. The lower edge of the wiper is flexibly yielding so as to apply a thin film of liquid material on a surface of the solidified layer and liquid material between solidified sections when displacing the wiper in the second direction.
Abstract: Nucleotide sequences from various species of Alexandrium are described. The sequences are used to construct nucleotide probes for assaying samples to determine the presence of selected species of Alexandrium.
Type:
Grant
Filed:
June 14, 1994
Date of Patent:
December 10, 1996
Assignee:
Woods Hole Oceanographic Institution
Inventors:
Donald M. Anderson, Christopher A. Scholin
Abstract: This dynamic programming includes a learning mode and an evaluation mode. In the learning mode, an accumulated DP path matrix is determined by a DP matching among a plurality of learning pattern vectors belonging to one category and a plurality of learning pattern vectors belonging to a similar category similar to the foregoing category and a standard pattern vector belonging to the foregoing category. Then path weights are calculated depending on the values of each element of the accumulated DP path matrix. In the evaluation mode, for performing a DP matching between evaluation pattern vectors and the standard pattern vector, a distance between elements of the above two pattern vectors is calculated with weighting by the above path weight. Thus, the optimum path in the evaluation mode is modified toward a frequent optimum path composed of a series of elements having high values in the foregoing accumulated DP path matrix.
Abstract: A film capacitor element produced from a metallized polyester film is described. In the metallized polyester film, the adhesion between a vapor-deposited metal layer and a polyester substrate is improved by providing a coating layer comprising a specific water soluble or water dispersible resin. The film capacitor produced by the use of the metallized polyester film has good moist heat resistance and long term stability in performance.
Abstract: A liquid crystal display device is disclosed. The display device uses a phase transition type guest-host mode. The device is made with a pair of substrates (31, 45). One substrate is a transparent substrate and having a transparent electrode (47) and an aligning film (48) formed in this order. The other substrate is located opposite to the transparent substrate and has an insulating film (34), a reflection plate (38), and an aligning film (44) formed in this order. The reflection plate has projections (42a,b) at the surface. The aligning films are subjected to a vertical aligning treatment relative to the respective substrates. A liquid crystal composition is disposed between the aligning films, and has a nematic liquid crystal, a chiral additive and a two-tone pigment. A helical pitch (P.sub.o) of the liquid crystal composition and the cell thickness (d) of the liquid crystal display device satisfy the relation of 1.5<d/P.sub.o .gtoreq.4.
Abstract: A method of fabricating a thin-film transistor, includes the step of forming a source region and a drain region in a semiconductor thin film having a capping film thereon, by accelerating a plasma source including hydrogen ions and one of Group III ions and Group V ions of the Periodic table, and simultaneously implanting the hydrogen ions and one of the Group III ions and the Group V ions into the semiconductor thin film, wherein there exist a plurality of peaks in a depth profile of a concentration of the hydrogen ions implanted into the semiconductor thin film having the capping film thereon and a second peak from a surface of the capping film among the plurality of the peaks is made to exist in the semiconductor thin film.
Abstract: A method of making a radiolabeled pyrimidine nucleoside or nucleotide is described. In the method an aqueous solution (i) a radioactive iodide, bromide, chlorine or astatide ion and (ii) a water soluble halomercuri pyrimidine nucleoside or nucleotide is contacted with an oxidizing agent, whereby a water soluble pyrimidine nucleoside or nucleotide labeled with radioactive iodine, bromine, chlorine or astatine is formed. Kits suitable for practicing the method are also disclosed.
Type:
Grant
Filed:
February 2, 1995
Date of Patent:
November 12, 1996
Assignee:
President U Fellows of Harvard College
Inventors:
Amin I. Kassis, Catherine F. Foulon, S. James Adelstein
Abstract: A magnetic resonance imaging (MRI) probe having an external background magnetic field B.sub.o is described. The probe has a primary magnet having a longitudinal axis and an external surface extending in the axial direction and a rf coil surrounding and proximal to the surface. The magnet provides a B.sub.o field having an external region of substantial homogeneity proximal to the surface. Preferably, the B.sub.o field is provided by two magnets spaced axially and in axial alignment and wherein said region of homogeneity intersects a plane located between the magnets and perpendicular to the axis. For MR imaging, surrounding the primary magnet are r-, z- and .o slashed.-gradient coils to provide spatial encoding fields.
Abstract: A training device for teaching a bird to recite words, sounds or music is described. The device has a digital recording and playback device for recording and playing a desired message, a pattern generator that controls the playing of the desired message for a predetermined number of times at predetermined intervals; and a controller for variably adjusting the time between playing intervals and the number of times the desired message is played at each playing interval.
Abstract: The present invention relates to the use of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other physiologically functional derivative thereof for the manufacture of a medicament for the treatment of tumours in animals, to pharmaceutical compositions for the treatment of tumours in animals, to pharmaceutical compositions for the treatment of tumours, comprising said compound as active ingredient and to a method of treating tumours in an animal which comprises administering to said animal an effective amount of said compound.
Abstract: A liquid crystal display device including a first substrate, a second substrate, and a sealing member for bonding the first and the second substrates, wherein a spacer for determining a thickness of a gap between the first and the second substrates is included only in the sealing member and wherein d<D where D is the thickness of the gap and d is the thickness of the sealing member. The gap is filled with a liquid crystal.
Abstract: It is an object of the invention to present a liquid crystal display device capable of displaying high precisely and brightly. The incident light into the reflection type liquid crystal display element is selectively varied by using the light selecting means, that is, cyan filter, magenta filter, and yellow filter, and red light, green light, and blue light are entered in every unit time. By controlling the reflection/cutoff of color lights of these three primary color by the reflection type liquid crystal display element, multicolor display of eight colors or full-color display is realized.
Abstract: The present invention relates to pharmaceutical compositions for the treatment of infections caused by Microsporidia comprising treating an animal with 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt thereof.
Type:
Grant
Filed:
June 9, 1995
Date of Patent:
October 1, 1996
Assignee:
Glaxo Wellcome Inc.
Inventors:
Winston E. Gutteridge, Alan T. Hudson, Victoria S. Latter, Mary Pudney
Abstract: The present invention relates to certain 2',3'-dideoxynucleosides and pharmaceutically acceptable derivatives thereof, methods for preparing them, their use in the treatment and prophylaxis of viral, especially retroviral, infections, and pharmaceutical formulations containing them.
Type:
Grant
Filed:
August 9, 1989
Date of Patent:
September 24, 1996
Assignee:
Glaxo Wellcome Inc.
Inventors:
George W. Koszalka, Thomas A. Krenitsky
Abstract: The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of protozoal infections caused by Kinetoplastida, Apicomplexa, Anaerobic protozoa and Mircosporidia comprising 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other functional derivative thereof as active ingredient and to a method of treating or preventing siad protozoal infections in an animal which comprises administering to said animal an effective amount of siad compound.
Type:
Grant
Filed:
November 8, 1994
Date of Patent:
September 24, 1996
Assignee:
Glaxo Wellcome, Inc.
Inventors:
Winston E. Gutteridge, Alan T. Hudson, Victoria S. Latter, Mary Pudney
Abstract: A water-dispersible tablet comprises lamotrigine, a pharmaceutically acceptable swellable clay and an additional disintegrating agent. The swellable clay and an additional disintegrating agent. The swellable clay is a smectite, e.g. Veegum F or bentonite, and is present within the granules of the tablet to provide a tablet which is capable of dispersing in water within 3 minutes to provide a dispersion which will pass through a 710 .mu.m sieve. The tablet can be optionally film-coated in which case the dispersion time is less than 5 minutes.